がん研セミナー (11月1日) のお知らせ

演題：Mutation-specific T cell therapies that prevent cancer relapse

演者：Professor Matthias Leisegang, Ph.D.（Institute of Immunology, Charité - Universitätsmedizin Berlin）

抄録：The adoptive transfer of T cells engineered with tumor-specific T cell receptors (TCRs) can effectively mobilize the immune system against cancer. In our group, we focus on neoantigen-specific T cell therapies that are personalized in its truest sense because suitable neoantigen targets and specific TCRs have to be identified for each patient individually. We make use of syngeneic animal models to develop mutation-specific T cell therapies that are designed to eradicate established cancer and thus prevent relapse. By treating primary cancers, we test different combination therapies necessary to overcome relapse often caused by the antigenic heterogeneity of established tumors. In order to shape clinical implementation, we use an HLA-A2-transgenic cancer model that facilitates the evaluation of TCR and antigen quality and thus the characterization of key parameters that determine therapeutic success. In my talk I will provide a brief overview about our projects and present current data.

日時：２０１９年１１月１日（金） １５：００〜１６：００

場所：吉田記念講堂

連絡先：清谷一馬（内線５３６２）

＊外部の研究者のご来聴を歓迎いたします。尚、本セミナーの内容は専門的であり、医学・生物分野の研究に携わる方を対象としております。